Insmed (NASDAQ:INSM) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $52.00 price objective (up from $43.00) on shares of Insmed in a report on Tuesday, April 9th. Canaccord Genuity set a $44.00 price objective on shares of Insmed and gave the stock a “buy” rating in a report on Friday, March 8th. ValuEngine downgraded shares of Insmed from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 5th. JMP Securities raised shares of Insmed from a “market perform” rating to an “outperform” rating and set a $40.00 price objective on the stock in a report on Friday, February 15th. Finally, Zacks Investment Research downgraded shares of Insmed from a “buy” rating to a “hold” rating in a report on Saturday, May 11th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $37.88.

NASDAQ INSM opened at $26.41 on Wednesday. Insmed has a 12-month low of $11.31 and a 12-month high of $33.13. The company has a debt-to-equity ratio of 2.48, a current ratio of 4.82 and a quick ratio of 4.69. The firm has a market capitalization of $2.02 billion, a P/E ratio of -6.33 and a beta of 2.98.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.02). The company had revenue of $21.90 million for the quarter, compared to analyst estimates of $19.61 million. On average, sell-side analysts expect that Insmed will post -3.7 earnings per share for the current year.

In other news, Director Donald J. Hayden, Jr. sold 6,286 shares of Insmed stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $32.99, for a total transaction of $207,375.14. Following the sale, the director now directly owns 68,483 shares in the company, valued at approximately $2,259,254.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alfred Altomari sold 5,500 shares of Insmed stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $30.00, for a total value of $165,000.00. Following the sale, the director now owns 25,942 shares in the company, valued at $778,260. The disclosure for this sale can be found here. Insiders have sold a total of 26,686 shares of company stock worth $790,767 over the last quarter. Company insiders own 4.95% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Dimensional Fund Advisors LP bought a new stake in shares of Insmed during the 3rd quarter worth $4,396,000. JPMorgan Chase & Co. raised its stake in shares of Insmed by 91.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 506,391 shares of the biopharmaceutical company’s stock worth $10,240,000 after purchasing an additional 241,921 shares during the period. Vanguard Group Inc. raised its stake in shares of Insmed by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,802,706 shares of the biopharmaceutical company’s stock worth $137,551,000 after purchasing an additional 154,130 shares during the period. Virtu Financial LLC bought a new stake in shares of Insmed during the 4th quarter worth $183,000. Finally, Rhumbline Advisers raised its stake in shares of Insmed by 46.9% during the 4th quarter. Rhumbline Advisers now owns 102,732 shares of the biopharmaceutical company’s stock worth $1,348,000 after purchasing an additional 32,813 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Article: What is a support level?

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.